Patents by Inventor Paula H. Culbreth

Paula H. Culbreth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6747064
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: June 8, 2004
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Publication number: 20020183398
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Application
    Filed: December 14, 2001
    Publication date: December 5, 2002
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 6359014
    Abstract: The present invention comprises preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: March 19, 2002
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5990241
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: November 23, 1999
    Assignee: CytRx, Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5696298
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 9, 1997
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5691387
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: November 25, 1997
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5523492
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: July 2, 1993
    Date of Patent: June 4, 1996
    Assignee: CYTRX Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE37285
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: July 17, 2001
    Assignee: Cytrx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE38558
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: July 20, 2004
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE36665
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: April 18, 2000
    Assignee: Cytrx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth